HARMONY BIOSCIENCES HOLDINGS, INC. Net Change in Cash
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Net Change in Cash of -$202.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-04
- HARMONY BIOSCIENCES HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$163.10M, a 553.10% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $36.00M, a 68.83% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $21.32M, a 51.74% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $44.18M.
- HARMONY BIOSCIENCES HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $299.50M, a 111.90% increase from fiscal 2024.
- HARMONY BIOSCIENCES HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $141.34M, a 109.72% increase from fiscal 2023.
- HARMONY BIOSCIENCES HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $67.40M, a 611.30% increase from fiscal 2022.
- HARMONY BIOSCIENCES HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $9.47M, a 66.87% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$202.73M 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | -$163.10M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $299.50M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $194.00M 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $93.05M 10-Q · filed 2026-08-04 | |||
| 2025-03-31 | $36.00M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $141.34M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $75.71M 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | $5.64M 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | $21.32M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $67.40M 10-K · filed 2026-02-24 | |||
| 2023-09-30 | $80.32M 10-Q · filed 2024-10-29 | |||
| 2023-06-30 | $73.13M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $44.18M 10-Q · filed 2024-04-30 | |||
| 2022-12-31 | $9.47M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $27.03M 10-Q · filed 2023-10-31 | |||
| 2022-06-30 | $2.22M 10-Q · filed 2023-08-01 | |||
| 2022-03-31 | -$9.81M 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | $5.68M 10-K · filed 2024-02-22 | |||
| 2021-09-30 | -$38.93M 10-Q · filed 2022-11-01 | |||
| 2021-06-30 | -$68.94M 10-Q · filed 2022-08-02 | |||
| 2021-03-31 | -$87.46M 10-Q · filed 2022-05-03 | |||
| 2020-12-31 | $204.17M 10-K · filed 2023-02-21 | |||
| 2020-09-30 | $197.28M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $51.82M 10-Q · filed 2021-08-10 | |||
| 2020-03-31 | $47.06M 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | -$58.82M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $18.00M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |